Is there diversity among UGT1A1 polymorphism in Japan?

Area of Science:

• Pharmacogenomics
• Human Genetics
• Molecular Biology

Background:

• The UDP-glucuronosyltransferase 1A1 (UGT1A1) enzyme plays a crucial role in drug metabolism.
• Polymorphisms in UGT1A1 and related genes (UGT1A7, UGT1A9) can affect drug efficacy and toxicity.
• Understanding population-specific genetic variations is essential for personalized medicine.

Purpose of the Study:

• To investigate the genetic diversity of UGT1A1, UGT1A7, and UGT1A9 polymorphisms across three distinct regions in Japan.
• To identify any potential genetic differences in these pharmacogene loci among Japanese populations.

Main Methods:

• Genotyping of 150 healthy volunteers (50 from Yamaguchi, Kochi, and Akita prefectures) using fragment size analysis, direct sequencing, and TaqMan assays.
• Analysis focused on specific polymorphisms including UGT1A1*28, UGT1A7*3, UGT1A9*22, UGT1A1*93, UGT1A1*6, UGT1A1*27, UGT1A1*60, and UGT1A7 (-57).

Main Results:

• No statistically significant regional diversity was observed for UGT1A1, UGT1A7, or UGT1A9 polymorphisms across the studied Japanese populations.
• A minor, statistically significant difference was noted in UGT1A1*6 heterozygosity, with the Akita population exhibiting higher rates (P = 0.0496).

Conclusions:

• The study concludes that there is a lack of significant regional genetic diversity in UGT1A1, UGT1A7, and UGT1A9 polymorphisms within Japan.
• These findings suggest a general genetic homogeneity for these key pharmacogenes across the Japanese population, with implications for drug response prediction.